Submit Deal

GALAPAGOS NV

Summary

Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. The company is based in Mechelen, Belgium.

Deals Overview

Total Deals4

Valued Deals4

Total Value£ 1.09 B

Avg. Deal Size£ 272 M

Market Context

Subsidiaries

FIDELTA

1 transaction

Senior Management

Onno van de Stolpe
CEO
Onno van de Stolpe
CEO
Paul Stoffels
CEO and Chairman

Sort

andre hoekema

Chief Business Operations Officer at GALAPAGOS NV

Manager

Deal

£ 849 M

Total Value

bart filius

CFO at GALAPAGOS NV

Manager

Deal

£ 849 M

Total Value

piet wigerinck

Chief Scientific Officer at GALAPAGOS NV

Manager

Deal

£ 849 M

Total Value

anna gibbins

Senior Director at GALAPAGOS NV

Manager

Deal

£ 28 M

Total Value

onno van de stolpe

CEO at GALAPAGOS NV

Manager

Deal

£ 849 M

Total Value

elizabeth goodwin

Vice President at GALAPAGOS NV

Manager

Deal

£ 28 M

Total Value

carmen vroonen

Communications Director at GALAPAGOS NV

Manager

Deal

£ 28 M

Total Value

onno van de stolpe

CEO at GALAPAGOS NV

Manager

Deal

£ 28 M

Total Value

sandra cauwenberghs

Senior Director Investor Relations at GALAPAGOS NV

Manager

Deal

£ 148 M

Total Value

marieke vermeersch

Vice President, Head of Global Corporate Communication at GALAPAGOS NV

Manager

Deal

£ 148 M

Total Value

sofie van gijsel

Senior Director at GALAPAGOS NV

Manager

Deals

£ 176 M

Total Value

thad huston

CFO and COO at GALAPAGOS NV

Manager

Deal

£ 148 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy